• Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma


45.500 GBp 1.250 2.82%

As of 11:35:25 ET on 09/17/2014.

Snapshot for Vernalis PLC (VER)

Open: 45.500 Day's Range: 45.500 - 45.500 Volume: 11,607
Previous Close: 44.250 52wk Range: 27.250 - 46.500 1-Yr Rtn: +52.30%

Stock Chart for VER

No chart data available.
  • VER:LN 45.500
  • 1D
  • 1M
  • 1Y
Interactive VER Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for VER

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. UKX -
Earnings Per Share (GBP) (ttm) -0.0290
Est. EPS (GBP) (12/2014) -0.0200
Est. PEG Ratio -
Market Cap (M GBP) 201.23
Shares Outstanding (M) 442.27
30 Day Average Volume 1,492,632
Price/Book (mrq) 2.4460
Price/Sale (ttm) 15.4682
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/01/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for VER

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for VER

Vernalis plc is a revenue generating development stage pharmaceutical company which has a broad pipeline of research and development programs. The Company is focused on developing products for the US prescription cough and cold market. The Company derives pipeline candidates both from collaborations with global pharmaceutical businesses and their own research activities.

Ian GarlandChief Executive OfficerDavid MackneyChief Financial Officer
Kevin KissaneSecretary
More Company Profile & Key Executives for VER

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil